SERCA Pharmaceuticals

In patients with acute myocardial infarction, restoration of blood supply can also lead to further heart damage and complications, a condition known as ischemic reperfusion injury (IRI). SERCA Pharmaceuticals AS develops a therapeutic agent for the restriction of IRI based on a new therapeutic strategy.  The small molecule candidate acts in a cardioprotective manner to restrict IRI during reperfusion after acute myocardial infarction.